EUDAMED – update on timelines
EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

EUDAMED

EUDAMED will provide a living picture of the lifecycle of medical devices available in the European Union (EU) market, while enhancing the overall transparency through better access to information and facilitating the coordination between EU Member States.

EUDAMED will be composed of six modules:

  • Actor registration;
  • Unique device identification (UDI)/ device registration;
  • Notified bodies and certificates;
  • Clinical investigations and performance studies;
  • Vigilance and Post-Market Surveillance,
  • Market Surveillance

In 2019, the European Commission clarified that EUDAMED will be completely functional only when all the modules are available and after confirmation of the functional specifications by an independent audit.

EUDAMED was originally scheduled to be launched in 2020, but it suffered several delays.

EUDAMED new timeline

On June 2022, the European Commission issued a new timeline planning for the EUDAMED.

Figure 1. EUDAMED new timeline

(adapted from “EUDAMED Timeline – The European Commission planning – June 2022″)

It is expected a minimally viable version of EUDAMED to be developed until the last quarter of 2023. 

The independent audit will be performed on the first two quarters of 2024.

A notice of the fully operationalization of the EUDAMED will be published in the Official Journal of the European Union in the second quarter of 2024.

After the publication of this notice, there is a transitional period of 6 months, which is expected to end by the last quarter of 2024. From that date, EUDAMED becomes mandatory as regards to obligations and requirements related to Actor Registration, Clinical Investigations and Performance Studies, Vigilance and Post-Market Surveillance and Market Surveillance.

All modules of EUDAMED will be mandatory by the second quarter of 2026.

References:

  1. EUDAMED Timeline – The European Commission planning – June 2022.

further
reading

cosmetic products

United Kingdom Restricts the Use of BHT in Cosmetic Products

The United Kingdom has taken a significant step in regulating the use of Butylated Hydroxytoluene (BHT) in cosmetic products. This move is crucial for distributors, manufacturers, and importers to ensure compliance and maintain the safety of their products in the UK market.

Read More »
cosmetic products

Great Britain Mandatory Classification List (MCL): cosmetic ingredients added.

On March 12, 2024, the Health and Safety Executive (HSE) updated the GB Mandatory Classification List (MCL) by adding 25 new chemical substances, as mandated by Article 37 of the GB Classification, Labelling and Packaging (CLP) Regulation. This update impacts substances identified as cosmetic ingredients with proposed Carcinogen, Mutagen, or Reprotoxic (CMR) classifications under Article 15 of the UK Cosmetics Regulation (UKCR). Notably, 2-ethylhexanoic acid and its zinc salt, along with Dimethyltolylamine, are among those facing potential bans and additions to the UK Cosmetics Regulation’s Annex II. These changes will come into effect on September 2, 2025.

Read More »
cosmetic products

New coating for TiO2 (nano) – is it safe?

The Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on new coating for Titanium Dioxide (nano). It declared the data was not enough to draw conclusions regarding the safety of this alternative coating, as more evidence of similarity to other nanomaterials is necessary.

Read More »
cosmetic products

New EU cosmetic restrictions on Cyclic Volatile Methyl Siloxanes (cVMS)

Cyclic volatile methyl siloxanes (cVMS) have raised environmental concerns because of their persistence and bioaccumulative properties. In light of these concerns, the European Union has extended restrictions on substances like D4, D5, and D6 in cosmetic products. New regulations will further limit the concentration of these compounds in both rinse-off and leave-on products, with compliance deadlines set for 2026 and 2027.

Read More »
cosmetic products

Citral under review: SCCS Preliminary Opinion

The SCCS was tasked by the European Commission to evaluate if the safety levels for Citral, determined through QRA2 based on skin sensitization induction, are sufficient to safeguard consumers. A preliminary opinion was released.

Read More »
cosmetic products

Are sunscreens with Benzophenone-4 safe?

Benzophenone-4 is commonly known as a UV-filter in cosmetic products. Learn what the final opinion of SCCS states about Benzophenone’s safety profile as a UV-filter in cosmetic products.

Read More »
cosmetic products

Is Aluminium in cosmetics safe for human health?

The Scientific Committee on Consumer Safety (SCCS) published its Final Opinion on the safety of Aluminium in cosmetic products. This follows a lengthy review process that began in 2013 when the SCCS was first mandated to evaluate the potential health risks of Aluminium (Al) and its compounds in cosmetics.

Read More »
cosmetic products

Silver in Cosmetics: SCCS preliminary opinion.

Ingredients: SILVER

The recent preliminary opinion from the Scientific Committee on Consumer Safety (SCCS) regarding silver in cosmetics is crucial for consumers and manufacturers. This article breaks down the key points, making it easier to understand the implications and stay informed.

Read More »
news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »